Accuray (ARAY) and Its Peers Financial Contrast
Accuray (NASDAQ: ARAY) is one of 83 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare Accuray to related companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, dividends and institutional ownership.
This is a breakdown of current ratings and target prices for Accuray and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accuray presently has a consensus price target of $6.60, suggesting a potential upside of 38.95%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.94%. Given Accuray’s higher probable upside, analysts plainly believe Accuray is more favorable than its peers.
Institutional & Insider Ownership
76.6% of Accuray shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 3.9% of Accuray shares are owned by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Accuray has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Accuray’s peers have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.
This table compares Accuray and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Accuray and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Accuray Competitors||$2.06 billion||$438.96 million||-76.08|
Accuray’s peers have higher revenue and earnings than Accuray. Accuray is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Accuray peers beat Accuray on 7 of the 12 factors compared.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.